EGFR and lung cancer: This cohort study examines whether osimertinib is associated with a higher incidence of cardiac toxic effects compared with earlier-generation epidermal growth factor receptor tyrosine kinase inhibitors among patients in Taiwan with EGFR-mutant non–small cell lung cancer.